Results 181 to 190 of about 16,072 (215)
Some of the next articles are maybe not open access.
Nitric oxide and cellular immunity in experimental cutaneous leishmaniasis.
Clinical and experimental dermatology, 2003We examined the local and systemic production of nitric oxide (NO) and the pattern of cytokine during the course of Leishmania mexicana infection in susceptible BALB/c and resistant C57BL/6 mice. NO derivatives were measured in serum, and the expression of inducible nitric oxide synthase (iNOS), interferon (IFN-gamma), interleukin (IL-4) and epidermal ...
N L, Díaz +5 more
openaire +3 more sources
Cytokine interactions in experimental cutaneous leishmaniasis.
Behring Institute Mitteilungen, 1991Destruction of intracellularly living Leishmania major amastigotes is achieved by activated macrophages. In this report, we have investigated the contribution of IL-4, TNF-alpha and IFN-gamma to the induction of antileishmanial macrophage activation.
W, Solbach +3 more
openaire +1 more source
Journal of Natural Products, 2018
Leishmaniasis is a neglected tropical disease caused by several different species of Leishmania. Treatment of leishmaniasis involves a limited drug arsenal that is associated with severe side effects, high costs, and drug resistance. Therefore, combination therapy has emerged as a strategy to improve leishmaniasis treatment.
Yago S. S. Emiliano +1 more
openaire +2 more sources
Leishmaniasis is a neglected tropical disease caused by several different species of Leishmania. Treatment of leishmaniasis involves a limited drug arsenal that is associated with severe side effects, high costs, and drug resistance. Therefore, combination therapy has emerged as a strategy to improve leishmaniasis treatment.
Yago S. S. Emiliano +1 more
openaire +2 more sources
The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis
Vaccine, 1999In a murine model of experimental cutaneous leishmaniasis, we investigated the protection elicited by injection of histone H1 isolated from parasites by perchloric extraction, of a H1 recombinant protein produced in E. coli, and of H1 long and short synthetic peptides, against infection by L. major.
N, Solioz +6 more
openaire +2 more sources
A new view on cutaneous dendritic cell subsets in experimental leishmaniasis
Medical Microbiology and Immunology, 2006Because of their anatomical distribution epidermal Langerhans cells (LCs) are discussed to be crucial for antigen uptake and subsequent presentation to naïve T cells in skin-draining lymph nodes. The use of LC-specific markers like Langerin or knock-in mice expressing green fluorescent protein under the control of the Langerin promotor now facilitates ...
Uwe, Ritter, Anke, Osterloh
openaire +2 more sources
Blood monocytes: Differing effector role in experimental visceral versus cutaneous leishmaniasis
Parasitology Today, 1994Irrespective of the tissue infected or the strain involved, all Leishmania species selectively parasitize and replicate within the resident tissue macrophage. Henry Murray here discusses the role of a second mononuclear phagocyte, the blood monocyte, which is also attracted to leishmanial lesions, but which appears to play quite different roles in ...
openaire +2 more sources
[Experimental models of cutaneous leishmaniasis in laboratory animals].
Parazitologiia, 1986A survey of literature on modelling cutaneous leishmaniasis of man (common and metastatic) on some lines of mice, guinea pigs, golden hamsters infected with different species of Leishmania is given. Merits and demerits of each described model are pointed out.
openaire +1 more source
Testing Experimental Compounds against American Cutaneous and Mucocutaneous Leishmaniasis
1982Abstract : Over a two year period eight WRAIR compounds have been tested against two subspecies of L. mexicana, three species of Leishmania braziliensis, and L. donovani. Five of these were 8-amonoquinolines, two were imidazoles, and the last was primaquine phosphate.
openaire +1 more source
Vaccination against experimental cutaneous leishmaniasis using attenuated Salmonella typhimurium
1995The Salmonella typhimurium vaccine construct, GIDl0l, which constitutively expresses L. major gp63 was used as an oral vaccine against experimental cutaneous leishmaniasis in the susceptible BALB/c mouse. After 2 oral immunisations with GID101, lesion development was reduced following L. major infection. This vaccine therefore represents a considerable
openaire +2 more sources
Modulation of Cell-Mediated Immunity in Experimental Cutaneous Leishmaniasis
1989It is now generally accepted that cell-mediated immunity plays a causal role in acquired resistance to leishmaniasis. This is based on an impressive range of clinical and experimental evidence (Table 1). Patients with active visceral leishmaniasis failed to respond to L.
openaire +1 more source